Weekly Recap | WuXi Biologics +10.16%, biosimilars deal in focus
I'm LongbridgeAI, I can summarize articles.The Week
WuXi Biologics (WXXWY.US) rose 10.16% this week to close at $12.38, while the S&P 500 fell 2.68%, leaving the stock about 12.84 percentage points ahead of the benchmark. The week started quietly around $11 on Monday and Tuesday, with Tuesday marking the low at $10.82. Wednesday brought a sharp gap up and an intraday high of $12.612 before settling at $12.48. Thursday saw a modest pullback to $12.25, and Friday closed back at $12.38. Weekly amplitude was 15.81%, and average daily volume of 53,942 shares ran about 31% above the 60-day median.
Key Events
The week revolved around biosimilars and broader sentiment in innovative drug names. On 2 November, Fresenius and WuXi Biologics entered an exclusive development agreement to expand the biosimilars pipeline. The next day, reports said WuXi Biologics signed a bundle covering exclusive options for 37 products. On 4 November, Hong Kong-listed innovative drug stocks strengthened, and WuXi Biologics surged more than 10% intraday. China Post Securities noted the pharmaceutical sector sits at historically relatively low valuations, while Guosen Securities research showed mutual funds added to CXO holdings in Q3. Citi maintained its buy rating on 5 November, and on 6 November an analysis suggested the biosimilars deal might change the investment case for the company.
The Week Ahead
The macro calendar is relatively busy: US wholesale sales on 9 November, then NFIB small business optimism and CPI readings on 10 November. For the company, the next earnings event is the Q3 FY2026 release on 25 November after the close, which should shed more light on how the biosimilars collaboration translates into orders and CXO pipeline momentum.
In Short
This week’s rally coincided with a warm CXO tape and fresh biosimilars headlines, though the latest session’s fund-flow snapshot showed no meaningful large-, medium- or small-lot activity, offering little directional signal. Valuation sits at roughly 3.59x book and about 35x earnings, neither extreme. The key questions ahead are whether the biosimilars partnership expands the order book and how next week’s CPI data affects risk appetite for global healthcare assets.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.